Full history for every metric is available with a Kvantra account
Glenmark Life Sciences Limited (GLS.NS)
Key financial summary
Financials in INR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | INR bn | 14 | 15 | 19 | 21 | 21 | 23 | 23 |
| Operating profit | INR bn | 9 | 4 | |||||
| Net profit | INR bn | 3 | 3 | 4 | 4 | 5 | 5 | 4 |
| EPS reported | INR | 38.38 | 35.96 | |||||
| Operating cashflow per share | INR | 33.75 | 33.75 | |||||
| Capex per share | INR | 10.53 | 10.53 | |||||
| FCF per share | INR | 23.22 | 23.22 | |||||
| Free cash flow | INR bn | 3 | 1 | |||||
| Net debt | INR bn | -3 | -5 | |||||
| Book value equity | INR bn | 23 | 25 | |||||
| Book value per share | INR | 190.1 | 206.5 | |||||
| Number of shares | m | 122.69 | 122.94 | |||||
| DPS (TTM paid) | INR | 22.50 | 0.00 |
Financial summary
Financials in INR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 20.24 | - | |||||
| P/B LTM | x | 4.12 | 5.24 | |||||
| P/S LTM | x | 4.21 | 5.85 | |||||
| P/FCF LTM | x | 33.81 | 252.93 | |||||
| EV/EBITDA LTM | x | 13.60 | 19.73 | |||||
| EV/Sales LTM | x | 4.09 | 5.62 | |||||
| Earnings Yield LTM | % | 4.94% | 3.54% | |||||
| FCF Yield | % | 2.96% | 0.40% | |||||
| Quality | ||||||||
| ROE | % | 20.19% | 21.07% | |||||
| ROIC | % | 27.81% | 27.81% | |||||
| Operating margin | % | 39.33% | 39.33% | |||||
| Gross margin | % | 54.45% | 54.45% | |||||
| FCF/Sales | % | 12.46% | 12.46% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +0.71% | -15.09% | |||||
| Sales Growth YoY | % | +6.29% | -3.97% | |||||
| Net Income Growth YoY | % | +0.84% | -14.95% | |||||
| FCF Growth | % | +98.69% | -24.63% | |||||
| Operating Profit Growth | % | +50.30% | -47.07% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 2.87% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 58.55% | 58.55% | |||||
| FCF/Debt | x | 16.59 | 3.29 | |||||
| Net Debt/EBITDA | x | -0.41 | -0.41 | |||||
| EBIT/Net interest | x | 580.80 | 580.80 | |||||
| Net debt/market cap | % | -3.13% | -3.98% | |||||
| Net debt/Equity | x | -0.13 | -0.21 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Glenmark Life Sciences Limited (GLS.NS)
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free